Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 CPT code 81237

EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646).

This code includes all analytical services related to the test. Additional procedures, such as microdissection, are reported separately. Modifier 26 can be used if only the interpretation and report are performed by a physician.

Modifier 26 can be appended if only the professional component (interpretation and report) is performed.

Medical necessity for this test is determined by the patient's clinical presentation and the potential impact of the test results on treatment decisions. Payer-specific guidelines should be consulted to determine coverage criteria.

The laboratory professional performs all technical aspects of this test, from sample preparation to analysis and reporting of results. A physician or other qualified healthcare professional may interpret the results.

IMPORTANT:For full gene sequencing of EZH2, use code 81236. Consider panel testing codes (e.g., 81450, 81455) if multiple genes are analyzed.

In simple words: This test looks for specific changes in your EZH2 gene. This gene can be involved in some cancers like lymphoma. The test helps doctors understand your prognosis and potential treatment options.

This code represents a laboratory test that analyzes the EZH2 gene for specific common variants, such as those found in codon 646. This test aids in the prognosis of conditions like diffuse large B-cell lymphoma, myelodysplastic syndrome, and myeloproliferative neoplasms. The procedure involves all analytical steps, from nucleic acid extraction to amplification and detection of variants.

Example 1: A patient with suspected diffuse large B-cell lymphoma undergoes testing for the EZH2 codon 646 mutation to assess prognosis and guide treatment decisions., A patient with myelodysplastic syndrome is tested for common EZH2 variants to determine disease progression and treatment response., A patient with a family history of EZH2-related cancers undergoes testing for common variants to assess their risk.

Documentation should include the patient's medical history, reason for testing, specific variants being analyzed, and the interpretation of the results. Any relevant clinical findings related to the conditions for which the test is being performed (e.g., diffuse large B-cell lymphoma) should also be documented.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.